Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Pharmacotherapy within a learning healthcare system: rationale for the Dutch Santeon Farmadatabase.

van de Garde EMW, Plouvier BC, Fleuren HWHA, Haak EAF, Movig KLL, Deenen MJ, van Hulst M.

Eur J Hosp Pharm Sci Pract. 2019 Jan;26(1):46-50. doi: 10.1136/ejhpharm-2017-001329. Epub 2017 Sep 18.

PMID:
31157095
2.

The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.

Poulussen FCP, Peters BJ, Hua KH, Houthuizen P, Grouls RJ, Deenen MJ.

Pharmacogenet Genomics. 2019 May 15. doi: 10.1097/FPC.0000000000000381. [Epub ahead of print]

PMID:
31107373
3.

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

de Man FM, Veerman GDM, Oomen-de Hoop E, Deenen MJ, Meulendijks D, Mandigers CMPW, Soesan M, Schellens JHM, van Meerten E, van Gelder T, Mathijssen RHJ.

Ther Adv Med Oncol. 2019 Apr 15;11:1758835919838964. doi: 10.1177/1758835919838964. eCollection 2019.

4.

The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.

Bury D, Ter Heine R, van de Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ.

Eur J Clin Pharmacol. 2019 Jul;75(7):921-928. doi: 10.1007/s00228-019-02657-6. Epub 2019 Mar 15.

PMID:
30877327
5.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
6.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.

PMID:
29430582
7.

The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.

Schijns W, Deenen MJ, Aarts EO, Homan J, Janssen IMC, Berends FJ, Kaasjager KAH.

Obes Surg. 2018 Jul;28(7):1997-2005. doi: 10.1007/s11695-018-3130-2.

PMID:
29404935
8.

Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia".

Deenen MJ, Henricks LM, Sonke GS, Schellens JH, Meulendijks D.

Tumour Biol. 2017 Jun;39(6):1010428317701629. doi: 10.1177/1010428317701629.

PMID:
28618970
9.

Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.

de Jong C, Sanders S, Creemers GJ, Burylo AM, Taks M, Schellens JHM, Deenen MJ.

Br J Clin Pharmacol. 2017 Sep;83(9):2120-2122. doi: 10.1111/bcp.13309. Epub 2017 May 31.

10.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

11.

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM.

Pharmacogenomics J. 2017 Oct;17(5):441-451. doi: 10.1038/tpj.2016.81. Epub 2016 Dec 20.

PMID:
27995989
12.

Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Deenen MJ, Meulendijks D.

Ann Oncol. 2017 Jan 1;28(1):184. doi: 10.1093/annonc/mdw533. No abstract available.

PMID:
27701067
13.

Reply to T. Magnes et al.

Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jul 10;34(20):2434-5. doi: 10.1200/JCO.2016.67.4374. Epub 2016 May 9. No abstract available.

PMID:
27161961
14.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH.

Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3.

15.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH.

Int J Cancer. 2016 Jun 1;138(11):2752-61. doi: 10.1002/ijc.30014. Epub 2016 Feb 19.

16.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

Meulendijks D, van Hasselt JGC, Huitema ADR, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JHM.

Eur J Cancer. 2016 Feb;54:120-130. doi: 10.1016/j.ejca.2015.10.013. Epub 2016 Jan 4.

PMID:
26761784
17.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, Gelderblom H.

Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Review.

PMID:
26716401
18.

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH.

Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Review.

PMID:
26603945
19.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.

PMID:
26573078
20.

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.

Deenen MJ, Meulendijks D, Boot H, Legdeur MC, Beijnen JH, Schellens JH, Cats A.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1285-95. doi: 10.1007/s00280-015-2872-y. Epub 2015 Oct 23.

PMID:
26499900
21.

Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.

Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH.

Int J Cancer. 2016 Jan 1;138(1):245-53. doi: 10.1002/ijc.29694. Epub 2015 Oct 1.

22.

Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.

Deenen MJ, de Kanter CT, Dofferhoff AS, Grintjes-Huisman KJ, van der Ven AJ, Fleuren HW, Gisolf EH, Koopmans PP, Drenth JP, Burger DM.

Ther Drug Monit. 2015 Dec;37(6):751-5. doi: 10.1097/FTD.0000000000000226.

PMID:
26102531
23.

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH.

Bioanalysis. 2015;7(5):519-29. doi: 10.4155/bio.14.304.

PMID:
25826134
24.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e201-7. doi: 10.1016/j.ijrobp.2012.12.008.

PMID:
23517808
25.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Ther Adv Med Oncol. 2013 Jan;5(1):91-2. doi: 10.1177/1758834012464806. No abstract available.

26.

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jan 15;913-914:30-40. doi: 10.1016/j.jchromb.2012.11.033. Epub 2012 Dec 7.

PMID:
23270936
27.

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].

Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH.

Ned Tijdschr Geneeskd. 2012;156(48):A4934. Dutch.

PMID:
23191966
28.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

29.

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(7):1006-20. doi: 10.1634/theoncologist.2010-0261. Epub 2011 Jun 9. Review.

30.

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(7):992-1005. doi: 10.1634/theoncologist.2010-0260. Epub 2011 Jun 9. Review.

31.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(6):820-34. doi: 10.1634/theoncologist.2010-0259. Epub 2011 May 31. Review.

32.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(6):811-9. doi: 10.1634/theoncologist.2010-0258. Epub 2011 May 31. Review.

33.

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A.

Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209. Epub 2011 Apr 15.

34.

Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

Deenen MJ, Terpstra WE, Cats A, Boot H, Schellens JH.

Ann Intern Med. 2010 Dec 7;153(11):767-8. doi: 10.7326/0003-4819-153-11-201012070-00023. No abstract available.

PMID:
21135311
35.

Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

Deenen MJ, Beijnen JH, Schellens JH.

J Clin Oncol. 2008 Oct 20;26(30):4997-8; author reply 4998-9. doi: 10.1200/JCO.2008.18.8565. Epub 2008 Sep 22. No abstract available.

PMID:
18809598
36.

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I.

Toxicol Appl Pharmacol. 2006 Feb 15;211(1):1-10. Epub 2005 Jun 21.

PMID:
15975613

Supplemental Content

Loading ...
Support Center